Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F57JB
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,257
Award facts
- Contract value 100% obligated
- $27,257.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $27,257.19 to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award based on open competition. The contract will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of January 14, 2026. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Logistics Agency's role in supplying pharmaceutical products to military healthcare systems.
This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999 through December 31, 2031. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities to support military healthcare programs worldwide. AmerisourceBergen, as a major pharmaceutical distributor and healthcare solutions provider, has demonstrated capability to meet federal procurement requirements through its extensive portfolio of medical product deliveries to federal agencies including the Defense Health Agency and U.S. Coast Guard.
Quick answers
Who was awarded contract SPE2DR26F57JB?
SPE2DR26F57JB was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26F57JB worth?
The government has obligated $27,257 on SPE2DR26F57JB.
Is contract SPE2DR26F57JB an order under another contract?
Yes. SPE2DR26F57JB is a delivery order under SPE2DR25D2006, an indefinite delivery contract.
Was contract SPE2DR26F57JB competed?
The extent of competition for SPE2DR26F57JB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award